We investigated whether in the Dutch situation adherence would be better, and whether a similar association with therapeutic complexity as found by Choudhry et al1 would be seen. From the PHARMO database we selected a sample of patients who initiated statin therapy between January 1 and December 31, 2004, and investigated whether therapeutic complexity predicted nonpersistence and poor drug-taking compliance after 12 months of follow-up.4 A patient was considered nonpersistent if a continuous gap of 60 days or more was present, and a patient had poor compliance if the Continuous Measure of Medication Acquisition (CMA) was lower than 80%.5 We used binary logistic regression to calculate the odds ratios for either nonpersistence or poor compliance. We investigated the following variables, calculated in the year previous to new statin use: (1) number of pharmacy visits, (2) number of medications filled, (3) number of long-term medication classes, (4) number of single medication dispensings (ie, single pharmacy pick-ups like an antibiotic course), (5) refill consolidation, (6) number of dose changes within each drug class, (7) number of prescribing physicians, and (8) number of switches within each drug class (eg, enalapril to ramipril). We included 6614 new statin users and identified 4189 statin users (63%) with a 60-day continuous gap during follow-up. Of the remaining 2425 continuous statin users, 111 (5%) had a CMA lower than 80%. The odds ratios and mean values for each investigated variable are presented in the Table for both persistence and compliance.